Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more cancer cells.

PURPOSE: This phase II trial is studying the side effects and how well combination chemotherapy works in treating young male patients with Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Christine Mauz-Körholz
• Collaborator: Martin-Luther-Universität Halle-Wittenberg
• Treatments: Cyclophosphamide; Doxorubicin; Etoposide; Liposomal doxorubicin; Prednisone; Vinblastine; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of classic Hodgkin's lymphoma (HL)

• Intermediate or advanced disease (stage I[E]-IV)

• No lymphocyte-predominant HL

• Previously untreated disease

PATIENT CHARACTERISTICS:

• Male

• No known hypersensitivity or contraindication to study drugs

• No other concurrent malignancies

• No severe concurrent diseases (e.g., immune deficiency syndrome)

• No known HIV positivity

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy or radiotherapy

• More than 30 days since prior and no other concurrent investigational drugs

• More than 30 days since prior and no concurrent participation in another clinical trial